Edward Flint v. Target Corporation ( 2010 )


Menu:
  •                  NOT RECOMMENDED FOR FULL-TEXT PUBLICATION
    File Name: 10a0037n.06
    No. 09-5153
    FILED
    UNITED STATES COURT OF APPEALS                                Jan 21, 2010
    FOR THE SIXTH CIRCUIT                             LEONARD GREEN, Clerk
    EDWARD H. FLINT,                                      )
    )
    Plaintiff–Appellant                           )
    )
    v.                                                    ) ON APPEAL FROM THE UNITED
    ) STATES DISTRICT COURT FOR THE
    TARGET CORPORATION,                                   ) WESTERN DISTRICT OF KENTUCKY
    )
    Defendant–Appellee.                           )
    )
    Before: MERRITT, MOORE, and GIBBONS, Circuit Judges.
    JULIA SMITH GIBBONS, Circuit Judge. Edward H. Flint appeals the district court’s
    grant of summary judgment for defendant Target Corporation (“Target”). Flint sued Target pro se
    on theories of negligence and product liability for the adverse physiological reactions he suffered
    allegedly as a result of taking prescription medication dispensed by his local Target pharmacy. The
    district court held that no genuine issue of material fact existed that could allow Flint to establish that
    Target breached the duty it owed him as a pharmacist and granted summary judgment on his
    negligence claim. Further, the district court found that Kentucky’s “middleman” statute, Ky. Rev.
    Stat. Ann. § 411.340, applied to Target to shield it from liability on Flint’s product liability claim.
    For the reasons that follow, we AFFIRM the judgment of the district court.
    In November 2006, Flint’s surgeon issued him a prescription for Pyridium (generic name:
    phenazopyridine). Flint filled the prescription and refilled it twice at the same Target pharmacy,
    which provided him a generic form of the drug each time. The company that manufactured the pills
    dispensed in the second refill, Contract Pharmacal for Breckenridge Pharmaceutical, was not the
    same company that had manufactured the pills in the first two fills. Each prescription fill was
    accompanied by a patient information sheet, which listed various contraindications, side effects, and
    possible indicia of an allergic or negative physiological reaction. Flint experienced no adverse
    effects from the first two fills, but shortly after taking pills from the third fill, Flint experienced what
    he believed to be an allergic reaction—itchy hives and bumps inside his mouth, a numb tongue, and
    a loss of taste. When Flint reported the reaction to the Target pharmacy, the pharmacy manager
    determined that there had been no error in the filling of the prescription, referred Flint to Target’s
    national customer service, and gave Flint a refund, the names and numbers of the manufacturers of
    the pills, and a list of the inactive ingredients in the pills dispensed in the third fill.
    Flint attempted to resolve his concerns directly with Target’s customer service department,
    but when Target did not help Flint to his liking, he filed the present suit on October 10, 2007. The
    suit was originally filed in Jefferson Circuit Court, but was promptly removed to federal court on
    October 30. Target moved for summary judgment on August 14, 2008, and the district court granted
    the motion on January 13, 2009. Flint v. Target Corp., No. 3:07CV-00600-R, 
    2009 WL 87469
    (W.D. Ky. Jan. 13, 2009). Flint timely appealed.
    We review de novo a district court’s grant of summary judgment. Williams v. Mehra, 
    186 F.3d 685
    , 689 (6th Cir. 1999) (en banc). Summary judgment is proper “if the pleadings, the
    discovery and disclosure materials on file, and any affidavits show that there is no genuine issue as
    to any material fact and that the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P.
    2
    56(c). The Court must review all the evidence, facts, and inferences in the light most favorable to
    the nonmoving party. Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 
    475 U.S. 574
    , 587 (1986).
    In order to defeat a summary judgment motion, the nonmoving party “must show sufficient evidence
    to create a genuine issue of material fact.” Prebilich-Holland v. Gaylord Entm’t Co., 
    297 F.3d 438
    ,
    442 (6th Cir. 2002). Entry of summary judgment is appropriate “against a party who fails to make
    a showing sufficient to establish the existence of an element essential to that party’s case, and on
    which that party will bear the burden of proof at trial.” Celotex Corp. v. Catrett, 
    477 U.S. 317
    , 322
    (1986).
    Flint argues that the district court erred in granting Target summary judgment. We find the
    district court’s reasoning and conclusions to be correct. On Flint’s negligence claim, under
    Kentucky law, pharmacists owe their customers the duty of care used by ordinarily skillful and
    prudent pharmacists under similar circumstances—in this case, to dispense the correct medication
    in accordance with the prescribing physician’s instructions. See Ohio County Drug Co. v. Howard,
    
    256 S.W. 705
    , 707 (Ky. 1923). As the district court found, all evidence presented indicates Target
    complied with that standard. Flint, 
    2009 WL 87469
    , at *3. Flint claims that the drugs he was given
    were not FDA-approved, but these statements are no more than bare allegations and do not suffice
    to defeat summary judgment. He also contends that Target breached its duty to him in the third fill
    by substituting a cheaper generic drug for another generic, but Target’s actions are actually
    authorized by Kentucky statute. See Ky. Rev. Stat. Ann. § 217.822. Flint further claims that Target
    had the duty to investigate and test any prescription medications it sold before dispensing them to
    3
    customers, but there is no law to support this assertion. Summary judgment on Flint’s negligence
    claim based on the element of breach was appropriate.
    On Flint’s product liability claims, the district court found that pharmacists in Kentucky are
    protected by the state’s “middleman statute.”1 Kentucky law provides that retailers are not liable in
    product liability actions if: “(1) the manufacturer [is] identified and subject to the Court’s
    jurisdiction, and (2) the product sold by the . . . retailer [was] unaltered from its original
    manufactured condition.” Salisbury v. Purdue Pharma, L.P., 
    166 F. Supp. 2d 546
    , 551 (E.D. Ky.
    2001). Exceptions to middleman protection exist if: “(1) . . . the . . . retailer breached an express
    warranty, or (2) . . . the . . . retailer knew or should have known at the time of distribution or sale that
    the product was in a defective condition and unreasonably dangerous.” 
    Id. The district
    court found
    that the two conditions were satisfied and neither exception existed, Flint, 
    2009 WL 87469
    , at *3–4,
    and we agree. Flint raises no arguments on appeal that contradict any of these conclusions, aside
    from an unsupported allegation that the middleman statute is unconstitutional.
    1
    Ky. Rev. Stat. Ann. § 411.340 provides:
    In any product liability action, if the manufacturer is identified and subject to the
    jurisdiction of the court, a wholesaler, distributor, or retailer who distributes or sells
    a product, upon his showing by a preponderance of the evidence that said product
    was sold by him in its original manufactured condition or package, or in the same
    condition such product was in when received by said wholesaler, distributor or
    retailer, shall not be liable to the plaintiff for damages arising solely from the
    distribution or sale of such product, unless such wholesaler, distributor or retailer,
    breached an express warranty or knew or should have known at the time of
    distribution or sale of such product that the product was in a defective condition,
    unreasonably dangerous to the user or consumer.
    4
    Flint also argues that the district court should have ruled on various nondispositive motions
    before granting summary judgment, including motions to compel discovery and to subpoena various
    witnesses for depositions. The district court, however, found that “[n]one of the discovery sought
    in the remanded motions would have materially affected this Court’s determination” on summary
    judgment. 
    Id. at *5.
    We agree, and affirm the district court on this ground as well.
    Finally, Flint argues that the district court erred by not allowing him to amend his complaint.
    We review a district court’s denial of a plaintiff’s motion for leave to amend his complaint for abuse
    of discretion. Evans v. Pearson Enters., Inc., 
    434 F.3d 839
    , 853 (6th Cir. 2006). However, “[w]hen
    the district court refuses the plaintiff’s request for leave to amend her complaint on grounds of
    futility, this court reviews de novo because the decision is based on a legal conclusion.” 
    Id. (citing Yuhasz
    v. Brush Wellman, Inc., 
    341 F.3d 559
    , 569 (6th Cir. 2003)). Flint filed separate motions for
    leave to amend in the district court. In the first motion, filed June 16, 2008, Flint sought to add
    greater detail to his complaint to supplement his claims against Target. In its summary judgment
    opinion, the district court held: “That motion has not been granted and, although it contains
    additional narrative, the tendered Amended Complaint does not contain additional causes of action,
    nor would it change the Court’s substantive analysis.” Flint, 
    2009 WL 87469
    , at *2 n.3. Because
    this is a holding that the amendment would have been futile, we review de novo. Upon examining
    the proposed amendments, however, we agree with the district court that the added details Flint
    provides would not help him establish a genuine issue of material fact on the issues that entitle
    Target to summary judgment.
    5
    Flint’s motion for leave to amend his complaint, filed August 28, 2008, sought to add two
    additional defendants, Breckenridge Pharmaceutical and Contract Pharmacal. The district court did
    not rule on this motion in its summary judgment decision. However, the district court docket reveals
    that all non-dispositive motions were referred to a magistrate judge on May 20, 2008, who, on
    September 30, 2008, ordered that “all pending non-dispositive motions are hereby administratively
    remanded without prejudice to the parties’ right to request that they be returned to the court’s active
    docket within 15 days after entry of any order denying Target’s request for summary judgment.”
    Flint had been advised that, in order to have any of his remaining motions decided, he needed to take
    action before the district court, which he never did. He did not appeal the magistrate’s order, nor did
    he include the order, this motion to amend, or any other motions in his notice of appeal.2 Therefore,
    we find that Flint has not properly preserved this argument or any other argument pertaining to
    undecided motions for appeal.
    For the reasons set forth above, we AFFIRM the district court’s grant of summary judgment.
    2
    Furthermore, any further consideration of the August 28 motion to amend would be futile,
    as the one-year limitations period that applies to product liability and negligence claims in Kentucky
    had run before the motion was filed. See Ky. Rev. Stat. Ann. § 413.140.
    6